Tal Danino, Ph.D.

Columbia Engineering say they have developed a new cancer therapy which pairs an engineered bacteria and an oncolytic virus to deliver a viral load directly into tumors to destroy them, while simultaneously evading the body’s immune defenses. The new therapy, described in Nature Biomedical Engineering, pairs the bacterium Salmonella typhimurium, with Senecavirus A (SVA), a virus that is known to preferentially infect and destroy cancer cells.

“We aimed to enhance bacterial cancer therapy by enabling the bacteria to deliver and activate a therapeutic virus directly inside tumor cells, while engineering safeguards to limit viral spread outside the tumor,” said co-lead author Jonathan Pabón, an MD/PhD candidate at Columbia… Continue reading.

WASHINGTON, D.C. – The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Tal Danino, Ph.D., Associate Professor of Biomedical Engineering at Columbia University to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to medical and biological engineers, comprised of the top two percent of engineers in these fields. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education.”

Professor Danino was nominated, reviewed, and elected by peers and members of the College of Fellows “for seminal contributions to the engineering of bacteria for cancer therapy, and unique global outreach through visual art projects…. Continue reading.